Comparative Pharmacology
Head-to-head clinical analysis: PRIMIDONE versus VIGAFYDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRIMIDONE versus VIGAFYDE.
PRIMIDONE vs VIGAFYDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Primidone is a barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and neuronal inhibition. It also has active metabolites, phenobarbital and phenylethylmalonamide, which contribute to anticonvulsant effects.
Irreversible inhibitor of GABA transaminase, increasing brain GABA levels.
Initial: 100-125 mg orally at bedtime for 3 days; increase to 100-125 mg twice daily for 3 days, then 100-125 mg three times daily for 3 days; maintenance: 250 mg three times daily. Maximum: 500 mg four times daily.
Adults: 50 mg/kg/day orally divided twice daily; maximum dose 3 g/day.
None Documented
None Documented
Primidone: 10-12 hours; phenobarbital metabolite: 48-120 hours; PEMA: 16-18 hours. Steady-state requires 4-7 days for primidone but up to 2-3 weeks for phenobarbital accumulation.
Clinical Note
moderatePrimidone + Digoxin
"The metabolism of Digoxin can be increased when combined with Primidone."
Clinical Note
moderatePrimidone + Digitoxin
"The metabolism of Digitoxin can be increased when combined with Primidone."
Clinical Note
moderatePrimidone + Torasemide
"The metabolism of Torasemide can be increased when combined with Primidone."
Clinical Note
moderatePrimidone + Etacrynic acid
"Primidone may increase the hypotensive activities of Etacrynic acid."
Terminal elimination half-life is 6-8 hours in adults; in neonates, it is prolonged to 16-20 hours due to immature renal function.
Renal: approximately 40% unchanged, 30% as phenobarbital, 20% as phenylethylmalonamide (PEMA); fecal: <5%
Renal excretion of unchanged drug accounts for approximately 65-70% of elimination; biliary/fecal excretion is minimal (<5%).
Category D/X
Category C
Anticonvulsant
Anticonvulsant